In addition, different from the approved anti-FGF23 monoclonal antibody treatment, in patients with XLH (10), AAV-cFGF23 did not affect blood levels of active vitamin D or the expression of key enzymes involved in its synthesis and degradation and did not trigger calcium deposition in the kidneys of Hyp-Duk mice. This evidence concerns the gene FGF23 and X-linked hypophosphatemia.